Efruxifermin reduces liver fat in NASH

Efruxifermin, a fibroblast growth factor-21 analog, helped patients with non-alcoholic steatohepatitis achieve reductions in liver fat and improved liver histology, lipid metabolism and glycemic control, according to research presented at The Liver Meeting Digital Experience.Stephen A. Harrison, MD, from Pinnacle Clinical Research, and colleagues conducted the phase 2a BALANCED study, a randomized controlled trial comprising 80 patients with biopsy confirmed NASH to assess the safety, efficacy and pharmacokinetics of Efruzifermin (EFX, Akero Therapeutics).In the study, investigators randomlyRead More

Share on facebook
Share on twitter
Share on linkedin